We’re proud to share that Robin Johnson, PharmD, Gene Therapy Submissions Lead at inSeption Group, was recently featured as an expert voice in the Philadelphia Business Journal’s Life Sciences Thought Leadership series — a platform reserved for leaders shaping the future of our industry.
Being included in this publication is more than a mention. It’s a recognition of the depth, specialization, and credibility required to guide today’s most advanced therapeutic programs. Gene therapy submissions demand a level of precision, strategic understanding, and real-world experience that few teams possess — and Robin’s perspective reflects exactly why inSeption is trusted to support these high-stakes programs.
The Business Journal brought together select experts across life sciences to weigh in on the challenges and opportunities defining the year ahead. Robin’s inclusion underscores not only her expertise, but the growing influence of inSeption’s approach to complex regulatory pathways.
This is a significant moment for our team — and an important conversation for anyone involved in advanced therapy development.
Read the full article in the Philadelphia Business Journal here:
